| Identification | More | [Name]
Ozagrel hydrochloride | [CAS]
78712-43-3 | [Synonyms]
(2E)-3-[4-(1H-IMIDAZOL-1-YLMETHYL)PHENYL]-2-PROPENOIC ACID HYDROCHLORIDE
(e)-3-(4-(1h-imidazol-1-ylmethyl)phenyl)-2-propenoic acid hydrochloride
OZAGREL HCL
OZAGREL HYDROCHLORIDE
(e)-3-(4-(1h-imidazol-1-ylmethyl)phenyl)-2-propenoicacidhydrochloridehydra
(e)-ohydrat
2-propenoicacid,3-(4-(1h-imidazol-1-ylmethyl)phenyl)-,monohydrochloride,mon
oky046hydrochloride
oky-046hydrochloride
OZAGREL HYDROCHLORIDE HYDRATE
OzagrelHcl99%
OzagrelHclC13H12N2O2.Hcl
(e)-3-[4-(imidazol-1-ylmethyl)phenyl]propenoic acid hydrochloride
OKY-046, (E)-3-[4-(Imidazol-1-ylmethyl)phenyl]propenoic acid hydrate hydrochloride
Ozagrel hydrate hydrochloride
Domenan
OKY-046 HCl
Vega | [EINECS(EC#)]
928-470-0 | [Molecular Formula]
C13H13ClN2O2 | [MDL Number]
MFCD06795644 | [Molecular Weight]
264.71 | [MOL File]
78712-43-3.mol |
| Chemical Properties | Back Directory | [Melting point ]
214-217° | [storage temp. ]
under inert gas (nitrogen or Argon) at 2-8°C | [solubility ]
H2O: soluble
| [form ]
solid
| [color ]
white to off-white
| [Water Solubility ]
H2O: soluble | [Merck ]
14,6980 | [Stability:]
Stable for 2 years from date of purchase as supplied. Solutions in distilled water may be stored at -20° for up to 1 month. | [CAS DataBase Reference]
78712-43-3(CAS DataBase Reference) |
| Hazard Information | Back Directory | [Description]
Ozagrel HCl (78712-43-3) is a potent and selective inhibitor of thromboxane (TXA2) synthetase (IC50 = 4 nM).1?Does not inhibit prostacyclin (PGI2) synthase, cyclooxygenase or PGE2?isomerase (IC50 > 1 mM).1?Inhibits platelet aggregation2?in vitro?and arachidonate-induced arterial contraction?in vivo. Ozagrel HCl protects against arachidonate-induced sudden death in the rabbit3, and alleviates liver injury induced by acetaminophen overdose in mice4. | [History]
Ozagrel hydrochloride was initially developed jointly by Ono Pharmaceutical Co., Ltd. and Kissei Pharmaceutical Co., Ltd. in Japan. Approved for marketing in Japan in 1988, it became the world's first commercially available potent thromboxane A2 (TXA2) synthase inhibitor. This medication is primarily indicated for the treatment of patients with ischaemic cerebrovascular disease, as it exhibits dual effects of inhibiting platelet aggregation and dilating blood vessels, thereby effectively preventing thrombus formation. | [Uses]
Antithrombotic;Thromboxane synthase inhibitor | [Definition]
ChEBI: Ozagrel hydrochloride is an organic molecular entity. | [IC 50]
TXA2/TP | [References]
1) Hiraku?et al. (1986),?Pharmacological studies on the TXA2?synthetase inhibitor (E)-3-[p-(1H-imidazol-1-ylmethyl)phenyl]-2-propenoic acid (OKY-046); Jpn. J. Pharmacol.,?41?393
2) Naito?et al. (1983), Effects of thromboxane synthetase inhibitors on aggregation of rabbit platelets; Eur. J. Pharmacol.,?91?41
3) Edmonds and Leffer (1984),?Protective actions of a new thromboxane synthetase inhibitor in arachidonate induced sudden death; Life Sci.,?35?1763
4) Tomishima?et al. (2013),?Ozagrel hydrochloride, a selective thromboxane A2?synthase inhibitor, alleviates liver injury induced by acetaminophen overdose in mice; BMC Gastroenterol.,?30?13 |
|
|